Tarceva Found To Benefit Older Lung Cancer Patients
A new drug has shown promise in the clinical trials involving lung can...The tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated e...Erlotinib is designed to specifically and potently block an overacti...The study involved 80 patients with either Stage IIIB or IV presenta...In addition all patients were evaluated for survival and toxicity; ...
A new drug has shown promise in the clinical trials involving lung cancer patients and it has even been proposed to evaluate the drug as a frontline therapy for those with lung cancer. One of the significant problems // faced in the treatment regime in the elderly patients is the tolerability and side effects of the drugs currently used.
The tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer according to researchers from Boston.
Erlotinib is designed to specifically and potently block an overactive growth-signaling molecule (EGFR) in cancer cells. The drug has also showed encouraging activity in patients with failed chemotherapy attempts. The present study is the first reported in the assessment of erlotinib in patients who have not received chemotherapy.
The study involved 80 patients with either Stage IIIB or IV presentation who were subjected to erlotinib treatment for 2 years. Almost 60 percent of the patients experienced either a partial response or had stable disease, though none of them had a complete response. The median survival was 46 weeks, and the median duration of partial response and stable disease was 65 weeks and 24 weeks, respectively.
In addition, all patients were evaluated for survival and toxicity; 69 were evaluated for best response. Ten patients discontinued from the study because of toxicity, and there was one treatment-related death from pneumonitis. Rashes (74%) and diarrhea (60 %) were the most common observed side effects.
Following success of the Phase II trials, the Phase III trial would be directed to comparing erlotinib with single-agent navelbine in the above mentioned population shortly.
In conclusion, erlotinib has been found to display encouraging activity and improve median survival in lung cancer patient '"/>
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
...ndition that requires extensive medical interventi...developing another grave condition known as Nephro...ermopathy (NSF/NFD). // First recognized as a dise...ckening or tightening of the skin, resulting in pa...
...eir memory during and after menopause, a change th...anges they weather during that time. // Now, rese... suggests that hormone therapy might help women re...tudy in the new issue of The Journal of Clinical E...
...ght or obese have increased blood pressure within ...ased long-term risk of kidney damage previously fo...eing presented at the American Society of Nephrolo...c Exposition in San Diego. "Our study demonstrated...
... letters to city, state and federal agencies claim...es were not stringent //enough in treating waste f...as mad cow and chronic wasting disease before it w... plant. A panel was set up at the request of the ...
(Date:8/27/2008)...at The Children,s Hospital at, Montefiore Provid...and Specialty Services, ... Every Heart Condition, NEW YORK, Aug. 27 /PRNews...tefiore (CHAM) is bringing the medical miracle of ...owing the recent approval of its,transplant center...
(Date:8/26/2008)...regon Tourism Commission,launched its new free onl...,(Q Care) this week on http://www.OregonQCare.com...o support the tourism and,hospitality industry thr...he importance of quality customer service, the tra...s to better serve Oregon,s visitors., "We,ve all ...
(Date:8/26/2008)...fore Pharmaceuticals Inc.,announced data presented...,Therapies in Cancer in Washington, D.C., showing ...geted PI3 kinase (PI3K) inhibitor SF1126, by,block... a very powerful pathway, the PI3/AKT /mTOR pathwa...er. Studies have shown that by,inhibiting this pat...
(Date:8/26/2008)... six weeks following surgical,treatment, ROSEMONT...ks following,bunion surgery, most patients, pain l...hind the wheel of a car again. A study published i... Joint Surgery ( http://www.jbjs.org/ ),also found...o underwent a,first metatarsal osteotomy (a common...
...on,s pipeline provide support for,epigenetic and c...I,data on use of Thalidomide to treat multiple mye...stCall/ -- Pharmion,Corporation reported today tha...the company,s marketed and pipeline products will ...of Clinical,Oncology,s (ASCO) 43rd Annual Meeting ...
...)--Jun 1, 2007 - A therapeutic,vaccine developed b... promises new hope for cancer patients. The result...be presented to an,international audience at the A...cal Oncology (ASCO) in Chicago, USA. ASCO is the,m...specialists,world-wide., The active substance VPM4...
HeartSpeed HB is the bi-plane cardiac system to meet interventional physicians' demands of Speedy and Simple operability on bi-plane cath lab with the latest dose reduction and top quality imaging ch
Kit for the Preparation of Technetium Tc 99m Sestamibi for injection
Stainless Steel
Olive Shaped Tip Cannula With Straight Shaft; in stainless steel.